Regorafenib Plus Pembrolizumab Misses PFS End Point in Microsatellite Stable CRC
January 22nd 2022Pembrolizumab plus regorafenib failed to demonstrate a significant improvement in progression-free survival in pretreated patients with microsatellite stable colorectal cancer (MSSCRC), missing the primary end point of the phase 1/2 trial.
It Is Time to Reexamine Control Arms in Phase 3 Trials
December 23rd 2021Maurie Markman, MD on strategies to appropriately evaluate small but clinically relevant patient subsets for whom traditional phase 3 randomized clinical trials are difficult, if not impossible, to complete in a realistically timely manner.
City of Hope Opens Oncolytic Virus Clinical Trial for Patients with Advanced Breast Cancer
November 19th 2021The trial is the first in the world offering this City of Hope-developed investigational therapy to patients with the hope of one day improving survival for people with triple-negative breast cancer.
Pevonedistat Plus Ibrutinib Showcases Preliminary Efficacy and Tolerability in CLL and MCL
October 21st 2021The investigational NEDD8-activating enzyme inhibitor pevonedistat in combination with ibrutinib demonstrated high response rates with a tolerable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma.
Challenges to Scientific Expertise: Future Implications for Oncology
October 12th 2021The continued uncertainties of the current and future status of the COVID-19 pandemic have resulted in a lack of trust in the authority of the scientific establishment in the United States, and elsewhere, as it operates during these difficult times.
Untangling Fact From Bias in the Age of Social Media and Mistrust
September 2nd 2021It is difficult to overstate the confusion associated with our nation’s messaging regarding a well-considered, rational, and scientifically based public health–focused approach to the current and future ramifications of the COVID-19 pandemic.